Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Biotechnology may be the stuff that dreams are made of, but more recently, the sector has been a nightmare for investors. Biotech is coming off one of its worst weeks in several years after the ...

Clearly there are a lot of people who love working in pharma and biotech — but why? Biotech companies have plenty of perks, sometimes including top-tier benefits like sabbaticals, unlimited ...

Join biotech commentators Daphne Zohar, Josh Schimmer, and Brad Loncar for a weekly discussion of all things biotech. From emerging trends and investment opportunities to the challenges facing the ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. PALO ALTO, Calif. — At an annual meeting usually focused on the industry ...

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions.

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech revealed plans to lay off 65% of its staff and operate with a skeleton ...

The comprehensive report from the bipartisan National Security Commission on Emerging Biotechnology (NSCEB) delivers a “sobering, even frightening,” conclusion: that China is quickly ascending to ...

Biotechnology is a rapidly growing sector of the United States and global economies. Its products are increasingly important in diagnosis, prevention, and treatment of disease. Visit the Professional ...

"Having those biotech skills already is going to help them ... "There's a lot of cool stuff making ground in the field of science, and I'm excited to see where it goes," Wherley said.